ES
CMPX icon

Enavate Sciences’s Compass Therapeutics CMPX Stock Holding History

Enavate Sciences’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.1M Hold
7,788,150
– – 4.94% 5
2026
Q1 		$41.2M Hold
7,788,150
– – 11.72% 4
2025
Q4 		$41.8M Hold
7,788,150
– – 8.25% 5
2025
Q3 		$27.3M Hold
7,788,150
– – 8.32% 6
2025
Q2 		$20.2M Hold
7,788,150
– – 11.47% 5
2025
Q1 		$14.8M Hold
7,788,150
– – 11.15% 6
2024
Q4 		$11.3M Buy
+7,788,150
New +$12.9M 8.11% 5

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Enavate Sciences's CMPX Position: Q2 2026 in Review

Enavate Sciences held its Compass Therapeutics (CMPX) position steady in Q2 2026 at 7,788,150 shares worth $17.1M. The position accounts for 4.94% of the portfolio, ranked #5.

Enavate Sciences first reported a position in CMPX in Q4 2024 and has held it in 7 quarters since. The position peaked at $41.8M in Q4 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Enavate Sciences held 7,788,150 shares of Compass Therapeutics worth $17.1M as of Q2 2026.
  • Enavate Sciences left its Compass Therapeutics share count unchanged in Q2 2026.
  • Compass Therapeutics made up 4.94% of Enavate Sciences's portfolio in Q2 2026, its #5 holding.
  • Enavate Sciences first reported a position in Compass Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Enavate Sciences's Compass Therapeutics position peaked at $41.8M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Enavate Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.